Juno Therapeutics

Bristol Myers Squibb takes its CAR-T patent case to US' top court in bid to revive $1.2B verdict against Gilead
Bristol Myers Squibb takes its CAR-T patent case to US' top court in bid to revive $1.2B verdict against Gilead
Fierce Pharma
Bristol Myers Squibb
Gilead Sciences
patents
CAR-T
Juno Therapeutics
Flag link:
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
Endpoints
JW Therapeutics
IPOs
CAR-T
liso-cel
China
Hong Kong
Juno Therapeutics
WuXi AppTec
Flag link:
Juno joint venture seeks IPO haul to bring CAR-Ts to China
Juno joint venture seeks IPO haul to bring CAR-Ts to China
Fierce Biotech
JW Therapeutics
Juno Therapeutics
WuXi AppTech
IPOs
Hong Kong
CAR-T
Flag link:
Sana Biotechnology raises more than $700M for cell, gene therapy efforts
Sana Biotechnology raises more than $700M for cell, gene therapy efforts
MedCity News
Sana Biotechnology
Juno Therapeutics
CAR-T
Flag link:
Motion denied: Gilead still on the hook for $1.5B in damages over CAR-T patent dispute with Bristol Myers Squibb
Motion denied: Gilead still on the hook for $1.5B in damages over CAR-T patent dispute with Bristol Myers Squibb
Endpoints
Gilead Sciences
CAR-T
Bristol-Meyers Squibb
Juno Therapeutics
patents
Flag link:
Bristol-Myers wins $752 million in U.S. patent case against Gilead
Bristol-Myers wins $752 million in U.S. patent case against Gilead
Reuters
Bristol-Myers Squibb
Gilead Sciences
Kite Pharma
patents
Juno Therapeutics
Flag link:
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Motley Fool
Celgene
Editas Medicine
Juno Therapeutics
CRISPR
gene editing
Flag link:
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Endpoints
Editas Medicine
Celgene
Juno Therapeutics
CRISPR
gene editing
immunotherapy
Flag link:
Grail’s Cook Steps Down, Former Juno Executive Bishop Named CEO
Grail’s Cook Steps Down, Former Juno Executive Bishop Named CEO
BioCentury
Grail
diagnostics
Juno Therapeutics
Celgene
Flag link:
Seattle life sciences industry has strength in numbers despite uncertainty
Seattle life sciences industry has strength in numbers despite uncertainty
Bizjournals
Seattle
Juno Therapeutics
Celgene
Flag link:
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Xconomy
Celgene
M&A
Juno Therapeutics
Kite Therapeutics
Bluebird Bio
Agios Pharmaceuticals
Jounce Therapeutics
BieGene
Acceleron
Flag link:
Ex-Juno execs launch cell therapy start-up Sana
Ex-Juno execs launch cell therapy start-up Sana
BioCentury
Sana Biotechnology
R&D
cell therapy
gene therapy
Juno Therapeutics
Flag link:
Juno investors eke out $24M settlement in lawsuit over CAR-T trial deaths
Juno investors eke out $24M settlement in lawsuit over CAR-T trial deaths
Fierce Pharma
Juno Therapeutics
JCAR015
CAR-T
Flag link:
3 Best Biotech Acquisitions of 2018 (So Far)
3 Best Biotech Acquisitions of 2018 (So Far)
Motley Fool
M&A
biotech
Celgene
Juno Therapeutics
Novartis
AveXis
Roche
Foundation Medicine
Flag link:
4 Huge Pharma Deals in 4 Months Is Just the Beginning
4 Huge Pharma Deals in 4 Months Is Just the Beginning
Motley Fool
M&A
Takeda
Shire
Novartis
AveXis
Sanofi
Bioverativ
Celgene
Juno Therapeutics
Flag link:
Cell therapy flotations could follow Kite and Juno buyouts
Cell therapy flotations could follow Kite and Juno buyouts
EP Vantage
cell therapy
Kite Pharma
Juno Therapeutics
M&A
Unum Therapeutics
Autolus
Flag link:
Treatment Debates Won’t Slow Down Biotechs
Treatment Debates Won’t Slow Down Biotechs
Barron's
biotech
Gilead Sciences
CAR-T
Juno Therapeutics
Bellicum
Flag link:
As CAR-Ts go from candidates to brands, what's the marketing strategy?
As CAR-Ts go from candidates to brands, what's the marketing strategy?
Medical Marketing and Media
CAR-T
drug marketing
JCAR017
Juno Therapeutics
Celgene
bb2121
Bluebird Bio
apalutamide
Janssen
Flag link:
With Celgene buyout, Juno CEO Hans Bishop set for monster payout of $287M
With Celgene buyout, Juno CEO Hans Bishop set for monster payout of $287M
Fierce Pharma
Celgene
Juno Therapeutics
Pharma CEOs
Hans Bishop
executive pay
Flag link:
Celgene Looking Good With Plans for More Growth
Celgene Looking Good With Plans for More Growth
Motley Fool
Celgene
Juno Therapeutics
Flag link:

Pages